Vanderbilt-Ingram Cancer Center has launched the nation’s first personalized cancer decision support tool, “My Cancer Genome,” to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients. This web-based information tool is designed to quickly educate clinicians on the rapidly expanding list of genetic […]
News: Personalized Cancer Medicine« Previous Page
Uniting Against Lung Cancer, a nonprofit organization dedicated to funding innovative lung cancer research in the United States and Canada, has awarded a $100,000 grant to Christine Lovly, M.D., Ph.D., a fellow in the Division of Hematology/Oncology at Vanderbilt-Ingram Cancer Center. The two-year grant will fund Lovly’s research on better treatment options for a subset […]
Paula Hart was just 46 when she starting having shortness of breath, along with a nagging cough and intermittent pain in her left shoulder. After a trip to the emergency room in her hometown of Evansville, Ind., and a series of additional tests, doctors finally diagnosed Hart with non-small cell lung cancer. The cancer was […]
Patients with metastatic melanoma being treated with the new investigational cancer drug PLX4032 are showing strong responses, with an 80 percent anti-tumor response rate among patients whose tumors are positive for the B-RAF (V600E) gene mutation. However, in all too many cases, patients are developing resistance to the drug and their cancer is beginning to […]
A new drug used to treat advanced melanoma patients with a specific genetic mutation in their tumors demonstrated significant tumor shrinkage in the majority of patients during a clinical trials.
A new documentary about the exciting era of personalized medicine and health care is now available on YouTube. Your Genome and the Future of Medicine, developed by Vanderbilt University Medical Center, initially aired on local stations in Lexington, Ky., and Nashville, Tenn. The 30-minute documentary, available for viewing in four segments, features interviews with several […]